162 related articles for article (PubMed ID: 6114964)
1. Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man.
MacGorman LR; Rizza RA; Gerich JE
J Clin Endocrinol Metab; 1981 Sep; 53(3):556-9. PubMed ID: 6114964
[TBL] [Abstract][Full Text] [Related]
2. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
Rizza RA; Cryer PE; Gerich JE
J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
[TBL] [Abstract][Full Text] [Related]
3. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
[TBL] [Abstract][Full Text] [Related]
4. Metabolic basis for the diabetogenic action of growth hormone in the obese (ob/ob) mouse.
Cameron CM; Kostyo JL; Adamafio NA; Dunbar JC
Endocrinology; 1987 Apr; 120(4):1568-75. PubMed ID: 3549265
[TBL] [Abstract][Full Text] [Related]
5. Amino-terminal peptide of growth hormone enhances insulin action in normal rats.
Mondon CE; Reaven GM; Ling N; Lewis UJ; Frigeri LG
Endocrinology; 1988 Aug; 123(2):827-33. PubMed ID: 3135175
[TBL] [Abstract][Full Text] [Related]
6. The effect of somatostatin on the hepatic extraction of insulin and glucagon in the anesthetized dog.
Ishida T; Röjdmark S; Bloom G; Chou MC; Field JB
Endocrinology; 1980 Jan; 106(1):220-30. PubMed ID: 7349954
[TBL] [Abstract][Full Text] [Related]
7. Glucose disposal during insulinopenia in somatostatin-treated dogs. The roles of glucose and glucagon.
Shulman GI; Liljenquist JE; Williams PE; Lacy WW; Cherrington AD
J Clin Invest; 1978 Aug; 62(2):487-91. PubMed ID: 670404
[TBL] [Abstract][Full Text] [Related]
8. Extrapancreatic effect of somatostatin infusion to increase glucose clearance.
Bergman RN; Ader M; Finegood DT; Pacini G
Am J Physiol; 1984 Sep; 247(3 Pt 1):E370-9. PubMed ID: 6148014
[TBL] [Abstract][Full Text] [Related]
9. Influence of growth hormone on glucose-induced glucose uptake in normal men as assessed by the hyperglycemic clamp technique.
Orskov L; Schmitz O; Jørgensen JO; Arnfred J; Abildgaard N; Christiansen JS; Alberti KG; Orskov H
J Clin Endocrinol Metab; 1989 Feb; 68(2):276-82. PubMed ID: 2563732
[TBL] [Abstract][Full Text] [Related]
10. Recombinant deoxyribonucleic acid-derived 22K- and 20K-human growth hormone generate equivalent diabetogenic effects during chronic infusion in dogs.
Ader M; Agajanian T; Finegood DT; Bergman RN
Endocrinology; 1987 Feb; 120(2):725-31. PubMed ID: 3542508
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin does not alter insulin-mediated glucose disposal.
Meneilly GS; Elahi D; Minaker KL; Rowe JW
J Clin Endocrinol Metab; 1987 Aug; 65(2):364-7. PubMed ID: 2885337
[TBL] [Abstract][Full Text] [Related]
12. Islet hormonal regulation of glucose turnover during exercise in type 1 diabetes.
Shilo S; Sotsky M; Shamoon H
J Clin Endocrinol Metab; 1990 Jan; 70(1):162-72. PubMed ID: 1967178
[TBL] [Abstract][Full Text] [Related]
13. Restoration of stable metabolic conditions during islet suppression in dogs.
Bradley DC; Bergman RN
Am J Physiol; 1992 Apr; 262(4 Pt 1):E532-8. PubMed ID: 1348903
[TBL] [Abstract][Full Text] [Related]
14. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.
Garrel DR; Moussali R; De Oliveira A; Lesiège D; Larivière F
J Clin Endocrinol Metab; 1995 Feb; 80(2):379-85. PubMed ID: 7888013
[TBL] [Abstract][Full Text] [Related]
15. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.
Larsson H; Holst JJ; Ahrén B
Acta Physiol Scand; 1997 Aug; 160(4):413-22. PubMed ID: 9338524
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion.
Campbell PJ; Bolli GB; Cryer PE; Gerich JE
N Engl J Med; 1985 Jun; 312(23):1473-9. PubMed ID: 2859524
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man.
Liljenquist JE; Mueller GL; Cherrington AD; Perry JM; Rabinowitz D
J Clin Endocrinol Metab; 1979 Jan; 48(1):171-5. PubMed ID: 422700
[TBL] [Abstract][Full Text] [Related]
19. Effect of ketone bodies on glucose production and utilization in the miniature pig.
Müller MJ; Paschen U; Seitz HJ
J Clin Invest; 1984 Jul; 74(1):249-61. PubMed ID: 6376544
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin increases hepatic insulin extraction.
O'Brien DW; Rajotte RV; Molnar GD; Toth K; Petersen TD
Diabetes Res; 1988 Apr; 7(4):171-8. PubMed ID: 2900090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
